Loading stock data…
AZN
$184.96-2.76 (-1.47%)
Pre-Market$183.83-1.13 (-0.61%)· Last close May 14
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AstraZeneca PLC in the Healthcare sector is trading at $184.96. Wall Street consensus targets $224.49 (10 analysts), implying a +21.4% move over the next 12 months. The stock is currently 13% below its 52-week high of $212.71, remaining 4.0% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +21.4% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$184.96
Potential Downside
21.8%
Whystock Fair Value$144.66
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus10 analysts
Mean target$224.49+21.4%
Range$184.00 – $245.00
Fundamentals
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys,...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$302.01B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
29.74
Beta
Defensive asset. Lower volatility than the S&P 500.
0.28
Div Yield
Strong income play. Yield provides a meaningful total return floor.
161.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
17.04%
Volume
Today's trading volume
970,304
Recent News
European Equities Traded in the US as American Depositary Receipts Tracking Higher in Thursday Trading
European equities traded in the US as American depositary receipts were moving higher late Thursday
Owkin Expands AstraZeneca Collaboration Around K Pro AI Platform
Agentic AI company Owkin said it signed a three-year licensing agreement with AstraZeneca Plc. (NASDAQ:AZN) to develop specialized biopharma AI agents using its K Pro platform, expanding the companies' existing collaboration in drug discovery and development. The agreement will allow Owkin to build end-to-end AI agents designed to operate within AstraZeneca's internal infrastructure and decision-making workflows. The companies said the tools are intended to support competitive intelligence and p
Will Keytruda Continue to Aid MRK's Growth in 2026 After a Strong Q1?
Keytruda aids Merck's Q1 performance with $8B in sales. New indications plus combo therapies could fuel the drug's overall growth through 2026.
Is AstraZeneca (LSE:AZN) Offering Value After Recent Share Price Pullback?
Wondering if AstraZeneca at £137.48 is offering fair value or if the price is running ahead of itself? This article walks through what the current valuation signals might mean for you. The stock is up 3.1% over the past week, while the past month shows a decline of 9.7%, with returns of 1.1% year to date and 37.4% over the last year, 20.9% over three years and 92.6% over five years. Recent headlines around AstraZeneca have focused on its role as a major global pharmaceuticals player, with...
Why the FDA’s push for real-time clinical trials could favor Big Pharma
The agency's new initiative promises faster drug approval times, but smaller trial sponsors could struggle to keep up.